Indication
Blasts 20-30 Percent of Bone Marrow Nucleated Cells
2 clinical trials
3 products
Clinical trial
Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic SyndromeStatus: Completed, Estimated PCD: 2023-03-16
Product
AzacitidineProduct
CB-839Clinical trial
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic SyndromeStatus: Recruiting, Estimated PCD: 2025-02-28
Product
Enasidenib